CADTH

pan-Canadian Oncology Drug Review Stakeholder Feedback on a pCODR Expert Review Committee Initial Recommendation (Patient Advocacy Group)

Polatuzumab Vedotin (Polivy) for Diffuse Large B-cell Lymphoma

April 21, 2021

CADTH

3 Feedback on pERC Initial Recommendation

Name of the Drug and Indication(s):	Polatuzumab vedotin (Polivy) In combination with bendamustine and rituximab for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, who are not eligible for autologous stem cell transplant and have received at least 1 prior therapy.
Eligible Stakeholder Role	Patient Organization
Organization Providing Feedback	Lymphoma Canada

** CADTH may contact this person if comments require clarification. Contact information will not be included in any public posting of this document by CADTH.*

3.1 Comments on the Initial Recommendation

a) Please indicate if the stakeholder agrees, agrees in part, or disagrees with the initial recommendation:

☒ Agrees ☐ Agrees in part ☐ Disagrees

Agree with the recommendation with clinical trial data indicating a net clinical benefit of Pola-BR with comparator BR, and meeting primary endpoints. Agree with recommendation that this treatment aligns with patient values as it offers longer remission and survival, and has manageable side effects as provided through patient feedback from Lymphoma Canada.

b) Please provide editorial feedback on the initial recommendation to aid in clarity. Is the initial recommendation or are the components of the recommendation (e.g., clinical and economic evidence) clearly worded? Is the intent clear? Are the reasons clear?

Page Number	Section Title	Paragraph, Line Number	Comments and Suggested Changes to Improve Clarity

3.2 Comments Related to Eligible Stakeholder Provided Information

Notwithstanding the feedback provided in part a) above, please indicate if the stakeholder would support this initial recommendation proceeding to final recommendation (“early conversion”), which would occur two business days after the end of the feedback deadline date.

☒ Support conversion to final recommendation.

Recommendation does not require reconsideration by pERC.

☐ Do not support conversion to final recommendation.

Recommendation should be reconsidered by pERC.

If the eligible stakeholder does not support conversion to a final recommendation, please provide feedback on any issues not adequately addressed in the initial recommendation based on any information provided by the stakeholder during the review.

Please note that new evidence will be not considered at this part of the review process, however, it may be eligible for a resubmission.

Additionally, if the eligible stakeholder supports early conversion to a final recommendation; however, the stakeholder has included substantive comments that requires further interpretation of the evidence, the criteria for early conversion will be deemed to have not been met and the initial recommendation will be returned to pERC for further deliberation and reconsideration at the next possible pERC meeting.

Page Number	Section Title	Paragraph, Line Number	Comments related to Stakeholder Information
6	Evidence in Brief	1, 9	The clinician submission through LC involved 7 clinicians, not 3 as stated
10	Patient values, experience on or expectations for treatment: Longer remission and survival, and improved QoL	1, 1-3	This sentence indicated all patents felt this way. “Patients indicated that that the dosing schedule of pola-BR was better than that used for other chemotherapy treatments as the number of treatments was reduced.” This was a quote from one patient. Please revise to: “One patient indicated…”